Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17993835 | 0.84 | KDM4E (0.46) | KDM4ETRPV1BAZ2B | |
| SCHEMBL1120432 | 0.84 | KDM4E (0.64) | MEN1KMT2AATMGAAKDM4E | |
| SCHEMBL17993837 | 0.83 | ADRA1A (0.45) | MEN1KMT2AKDM4ETRPV1BAZ2B | |
| SCHEMBL18033535 | 0.83 | KDM4E (0.44) | MEN1KMT2AKDM4ETRPV1BAZ2B | |
| SCHEMBL17993875 | 0.81 | MEN1 (0.55) | MEN1KMT2AATMGAATRPV1 | |
| SCHEMBL16624099 | 0.81 | HTR7 (0.58) | MEN1KMT2AATMGAAKDM4E | |
| SCHEMBL16624095 | 0.80 | KIF11 (0.46) | KDM4ETRPV1MAPK10RIPK1MCHR1 | |
| SCHEMBL8261111 | 0.79 | KDM4E (0.69) | MEN1KMT2AKDM4ETRPV1 | |
| SCHEMBL5376602 | 0.77 | TRPV1 (0.56) | MEN1KMT2ATRPV1BAZ2BMAPT | |
| SCHEMBL11670415 | 0.77 | BAZ2B (0.53) | MEN1KMT2AGAAKDM4EBAZ2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| WO-2015050212-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 日産化学工業株式会社 | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | MEN1 1968/4885KMT2A 4070/4885ATM 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.